Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

被引:21
|
作者
Fabi, Alessandra [1 ]
Giannarelli, Diana [2 ]
Malaguti, Paola [1 ]
Ferretti, Gianluigi [1 ]
Vari, Sabrina [1 ]
Papaldo, Paola [1 ]
Nistico, Cecilia [1 ]
Caterino, Mauro [3 ]
De Vita, Roy [4 ]
Mottolese, Marcella [5 ]
Iacorossi, Laura [6 ]
Cognetti, Francesco [1 ]
机构
[1] Regina Elena Inst Canc Res, Dept Med Oncol, Rome, Italy
[2] Regina Elena Inst Canc Res, Biostat Unit, Rome, Italy
[3] Regina Elena Inst Canc Res, Serv Radiol, Rome, Italy
[4] Regina Elena Inst Canc Res, Operat Unit Plast & Reconstruct Surg, Dept Pathol, Rome, Italy
[5] Univ Roma Tor Vergata, Dept Pathol, Rome, Italy
[6] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2015年 / 9卷
关键词
nab-paclitaxel; metastatic breast cancer; anthracyclines; PHASE-II TRIAL; CHEMOTHERAPY; GUIDELINES; DOCETAXEL; SURVIVAL; WOMEN;
D O I
10.2147/DDDT.S89575
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: There is a deep need to improve the care of metastatic breast cancer (MBC) patients, since even today it remains an incurable disease. Taxanes are considered the most effective cytotoxic drugs for the treatment of MBC, both in monotherapy and in combined schedules, but the need for synthetic solvents contributes to the severe toxicities and may have a negative impact on the efficacy. Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) is a colloidal suspension of paclitaxel and human serum albumin initially developed to avoid the toxicities associated with conventional taxanes. Patients and methods: The aim of this prospective, single-center open-label, noncomparative study was to evaluate the efficacy and safety of nab-paclitaxel in MBC patients pretreated with taxanes. The patients were treated with nab-paclitaxel as a single agent, 260 mg/m(2) on day 1 of each 3-week cycle or 125 mg/m(2) weekly. The primary endpoint was the overall response rate (ORR). Secondary objectives were duration of response, clinical benefit rate, progression-free survival (PFS), overall survival, and safety. Results: A total of 42 patients (median age 48 years, median Eastern Cooperative Oncology Group performance status 0, triple-negative MBC 19%, all pretreated with a taxane-based therapy, mainly in advanced disease) were enrolled in the study. The ORR was 23.8%, including one complete response (2.4%) and nine partial responses (21.4%); the disease control rate was 50%. The median duration of response was 7.2 months. After a median follow-up of 9 months, the median PFS was 4.6 months. ORR and PFS were similar irrespective of the previous chemotherapy lines, metastatic sites, and biomolecular expression. Nab-paclitaxel was well tolerated, and the most frequent treatment-related toxicities were mild to moderate (grades 1-2). Conclusion: This real-life study shows that nab-paclitaxel has a significant antitumor activity and a manageable safety profile in patients pretreated with taxanes and experiencing a treatment failure after at least one line of chemotherapy.
引用
收藏
页码:6177 / 6183
页数:7
相关论文
共 50 条
  • [41] Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer
    Kashiwada, Takeru
    Saito, Yoshinobu
    Terasaki, Yasuhiro
    Hisakane, Kakeru
    Takeuchi, Susumu
    Sugano, Teppei
    Miyanaga, Akihiko
    Noro, Rintaro
    Minegishi, Yuji
    Seike, Masahiro
    Kubota, Kaoru
    Gemma, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (02) : 165 - 173
  • [42] Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer A protocol for systemic review and meta-analysis
    Li, Bingxue
    Chen, Xinjie
    Ding, Tongjing
    Liu, Yihua
    Ma, Tingting
    Zhang, Ganlin
    Wang, Xiaomin
    MEDICINE, 2021, 100 (07) : E24514
  • [43] Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer
    Matsui, Akira
    Tatibana, Akihiko
    Suzuki, Noriyuki
    Hirata, Masaru
    Oishi, Yoko
    Hamaguchi, Youhei
    Murata, Yuya
    Nagayama, Aiko
    Iwata, Yuko
    Okamoto, Yasushi
    ANTICANCER RESEARCH, 2017, 37 (11) : 6481 - 6488
  • [44] Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer
    Yamane, Hiroaki
    Itagaki, Tomoko
    Kajitani, Keiko
    Koura, Yuji
    Kawabuchi, Yoshiharu
    Ohara, Masahiro
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 1121 - 1128
  • [45] A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma
    Li, Yifan
    Zeng, Jing
    Huang, Manni
    An, Jusheng
    Bai, Ping
    Wu, Lingying
    Zhang, Rong
    CANCER, 2017, 123 (03) : 420 - 425
  • [46] Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer A retrospective observational study
    Oi, Hajime
    Matsuda, Toshiaki
    Kimura, Tomoki
    Morise, Masahiro
    Yamano, Yasuhiko
    Yokoyama, Toshiki
    Kataoka, Kensuke
    Kondoh, Yasuhiro
    MEDICINE, 2022, 101 (06) : E28863
  • [47] Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer
    Zhang, Weiwei
    Wang, Ye
    He, Jinzhi
    Xu, Yinggang
    Chen, Rui
    Wan, Xinyu
    Shi, Wenjie
    Huang, Xiaofeng
    Xu, Lu
    Wang, Jue
    Zha, Xiaoming
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2023, 54
  • [48] A clinical retrospective study of anlotinib in combination with gemcitabine and albumin-bound paclitaxel for the first-line treatment of advanced pancreatic cancer
    Zheng, Yawen
    Zhou, Yuhan
    Xia, Haiyan
    Liang, Wei
    Wei, Xiaowei
    Zhou, Jin
    GASTROINTESTINAL TUMORS, 2025, 12
  • [49] Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer
    He, Ming-ming
    Wang, Feng
    Jin, Ying
    Yuan, Shu-qiang
    Ren, Chao
    Luo, Hui-yan
    Wang, Zhi-qiang
    Qiu, Miao-zhen
    Wang, Zi-xian
    Zeng, Zhao-lei
    Li, Yu-hong
    Wang, Feng-hua
    Zhang, Dong-sheng
    Xu, Rui-hua
    CANCER SCIENCE, 2018, 109 (11) : 3575 - 3582
  • [50] Efficacy and safety of pyrotinib in combination with albumin-bound paclitaxel for the treatment of HER2-positive advanced breast cancer: A real-world study
    Yang, Lixian
    Zheng, Lei
    Kong, Fanting
    Tian, Xinli
    Zhang, Shiyu
    Pu, Pengpeng
    ONCOLOGY LETTERS, 2023, 26 (01)